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ABSTRACT
Objective: To investigate clinical, biomechanic and his-
tomorphometric effects of zoledronic acid on osteopo-
rotic rats’ tibiae after bilateral ooforectomy. Methods: 
40 female Wistar (Rattus novergicus albinus) rats were 
prospectively studied. On the 60th day of life, the ani-
mals were randomized into two groups according to the 
surgical procedure: bilateral ooforectomy (O) (n=20) and 
sham surgery (“sham”) (P) (n=20). After 30 days, the 
animals were divided into four groups, according to the 
administration of zoledronic acid (ZA) 0.1mg/kg or distil-
led water (DW): OZA (n=10), ODW (n=10), PZA (n=10) 
and PDW (n=10). After 12 months, the animals were 
sacrificed, and had their tibiae assessed. In the clinical 
study, animals’ weight was considered; in the biomecha-
nical study, compressive assays were applied and, in the 
histomorphometric analysis, the bone trabecular area was 
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determined. Results: “O” groups showed a significantly 
greater weight gain than “P” groups (p=0.005). Groups 
OZA and PZA showed an insignificant weight gain when 
compared to ODW (p=0.47) and PDW (p=0.68). The 
groups receiving zoledronic acid and distilled water 
were able to bear maximum load, similar (p=0.2), at the 
moment of fracture. In the groups receiving zoledronic 
acid, an insignificant increase of the bone trabecular 
area was found when compared to the groups receiving 
distilled water (p=0.21). There was a positive correlation 
between trabecular area and maximum load (p=0.04; 
r=0.95). Conclusion: Zoledronic acid did not signifi-
cantly influence animals’ weight. The results showed 
an insignificant increase both of the tibial shaft bone 
resistance and the bone trabecular area.
Keywords – Osteoporosis; Biomechanics; Tibia; Expe-
rimental epidemiology; Wistar rats; Prospective studies
INTRODUCTION
The technological changes, medical advances, and 
urbanization that have occurred in Brazil during the 
last century have led to an increased life expectancy 
of the general population allowing it to age (*)(1,2). 
Moreso than demographics alone, the significant in-
crease in the elderly portion of the population requi-
res new and efficient investments in public health. 
Chronic and degenerative diseases are becoming in-
creasingly common, and among them, osteoporosis is 
playing an important role(3).
Caused mainly by the loss of the homeostatic ba-
lance of bone tissue, osteoporosis is an asymptomatic 
disease. In most cases, the disease manifests itself 
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daily and kept in a cool dry place with 24°C con-
trolled temperature and 12 hour light/dark cycles. 
Animals were offered rodent feed (Labina®, Nestle 
Purina PetCare Company©) and water ad libitum.
At 60 days, after reaching sexual maturity, rats 
were identified by perforations on the right and left 
auricular region and randomized, by drawing of sealed 
opaque envelopes, into two groups according to the 
surgical procedure to which they would be submitted: 
the oophorectomy group (O) (n = 20) and the sham 
surgery group (P) (n = 20).
The castration procedure was performed after 
intraperitoneal anesthesia, using 30 mg/kg of sodium 
pentobarbital 3% and bilateral trichotomy just below 
the last rib, dorso-laterally. The animals underwent 
washing with soap and water, antisepsis with a tincture 
of polyvinylpyrrolidone-iodine (PVPI-tincture), and were 
positioned on the operating table in lateral recumbency. 
After placement of a sterile field eyepiece, a longitudinal 
incision approximately 1.5 cm in length was made 
between the last rib and the hip joint. With the aid of 
tweezers, the peritoneal cavity was exposed, surpassing 
the muscular plain by divulsion, allowing access to the 
ovary surrounded by adipose tissue (Figure 1).
The ovary was ligated with 3.0 cotton thread and 
sectioned distal to the ligation. The musculature and 
skin were approximated with 4.0 nylon suture, and 
the same procedure was repeated on the contralateral 
side to remove the other ovary. The animals in group 
P underwent the same surgical procedures described, 
excepting the time of surgical ligation and sectioning 
of the ovaries.
1. (*) Brazilian Institute of Geography and Statistics (IBGE, Instituto Brasileiro de Geografia e Estatística). Projection of the Brazilian population. Brazil already 
has more than 180 million inhabitants. [Social communication, August 30, 2004]. IBGE 2004.
Figure 1 – Appearance of the clamping of the ovary in the middle 
of adipose tissue prior to ligation and section.
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initially by the occurrence of fractures, especially of 
the vertebrae, femur, and distal radius(4-6).
Prevention is the treatment of choice. It is well- 
known that building bone reserves during youth is 
a primary factor for the onset of osteoporosis(5-7). In 
some cases, drug therapy becomes the most effective 
measure to reverse or, more commonly, to prevent 
disease progression(5,8,9). There are currently two ma-
jor classes of drugs: inhibitors of bone resorption and 
bone formation stimulants(8).
The most well established representatives of the 
class of inhibitors of bone resorption are bisphospho-
nates, which by blocking osteoclastic activity are es-
pecially useful in diseases that manifest by rapid bone 
turnover(10,11). Among the drugs in this therapeutic 
class, those called the amino-bisphosphonates or third-
generation bisphosphonates, are up to 10,000 times 
more potent than the best known bisphosphonates(12-14).
Zoledronic acid (zoledronate), a new bisphosphonate, 
with a dose of 5 mg per year via intravenous infusion, is 
indicated for being able to reduce the side effects of the 
daily use of this pharmacological class and to eliminate 
the low adherence of patients to treatment(15,16).
The few existing publications relate zoledronic 
acid to the prevention of osteoporotic fractures in 
the spine and proximal femur(17-19). The aim of this 
study was to evaluate the effect of zoledronic acid in 
a single annual dose on the tibial diaphysis of oopho-
rectomized rats through clinical, biomechanical, and 
histomorphometric studies.
METHODS
All procedures were approved by the Animal Ex-
periments Ethics Committee of the Botucatu School 
of Medicine, SP, under the case number 622/2007. 
Forty sexually mature virgin Wistar rats (Rattus nor-
vegicus albinus) from the Central Vivarium of the 
São Paulo State University (UNESP, Universidade 
Estadual Paulista “Julio de Mesquita Filho”), Botu-
catu Campus, were used.
After being clinically assessed and weighed, the 
animals were housed in groups of five in eight poly-
propylene cages with metal screen covers and lined 
with autoclaved pine shavings. These were cleaned 
63
At 90 days of life and after a new randomization, 
groups O and P were divided into four subgroups 
according to the intraperitoneal administration of either 
the recommended dose of 0.1 mg/kg(17,20) zoledronic 
acid (ZA) (Aclasta™, Novartis® Biosciences Inc.) or 
distilled water (DW), as follows: OZA (n = 10), ODW 
(n = 10), PZA (n = 10) and PDW (n = 10). A sterile 
insulin syringe was used to administer the substances, 
with Injex Stilly Line® fixed needles (1ml/cc, 0.30 x 
12.7 mm – 30G 1/2’’ needle).
Twelve months after the administration of zole-
dronic acid or distilled water, the animals were eu-
thanized with a lethal intraperitoneal dose of 80 mg/
kg of sodium pentobarbital 3%.
After euthanasia, the tibiae of the animals were 
disarticulated at the proximal (knee) and distal (ankle) 
regions, with the soft tissues (muscles, tendons, and 
ligaments) removed. For biomechanical testing, the 
right tibiae were wrapped in aluminum foil, labeled, 
and frozen for 24 hours in a domestic refrigerator at 
a temperature of –20°C. The left tibiae were placed 
in clean and properly identified glass containers, and 
fixed in 10% formaldehyde solution for histomor-
phometric study.
Clinical study: performed by analysis of the 
animals’ body mass(g). Measurements were made 
monthly and always on the same day throughout the 
experiment, using a digital scale with a capacity of 
six kilograms-force and a range of 5 g. The scale was 
calibrated quarterly by trained personnel.
Biomechanical study: to determine the mechanical 
properties of the tibiae, bending tests were conducted 
at three points, using an EMIC® universal testing ma-
chine model DL 10,000, with an accuracy of (0.018 
+ F/3700)KN, ascertained in accordance with ABTN, 
NBR6156, and NBR6674 standards. The machine 
operates in conjunction with a computer under the 
Windows™ 2000 operating system, under which the 
Mtest version 1.00 program was used for measuring 
the results. In the 12 hours prior to biomechanical test-
ing, the right tibiae were thawed and kept in bandages 
soaked in 0.9% saline. The bones were individually 
supported horizontally at their ends on two wooden 
blocks. The standard distance between the two points 
of support was set at 2/3 the length of the specimen. 
The blade was positioned halfway between the ends on 
the concave face of the tibiae (Figure 2). To determine 
the maximum load supported by the body, the blade 
was set into motion at a speed of 30mm/min(21,22). The 
calculation of the maximum load was performed au-
tomatically by the program (Chart 1).
Figure 2 – Detail of the specimen at rest and the load application 
blade positioned halfway between the ends.
Chart 1 – Load-strain diagram obtained during the bending test.
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Histomorphometric study: after decalcification, 
dehydration, diaphanization, and embedding in paraffin, 
the left tibiae were sliced transversally in the middle 
third and stained with hematoxylin-eosin (HE)(23). The 
slides were placed under a microscope (Laica®) coupled 
to a video monitor with a resolution of 1024x768 
pixels, which sent the digital images to a computer. 
 !"# $%&'"()*&%#'+,"#&%"&# -./2) was calculated using 
a 5X lens and the Image Pro Plus® image analysis 
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USA) in two standard fields of the central region 
of the tibial diaphysis, after manual delimitation 
of the perimeter of the trabeculae (Figure 3). 
The calculation of the total area was carried out 
automatically by the program(24).
Figure 3 – Appearance of the histological cross-tibial diaphysis 
slice (HE, 20X), after manual delimitation of the perimeter of 
trabeculae.
Statistical analysis: was performed by analysis 
of variance (parametric or nonparametric), in a com-
pletely randomized model, complemented by mul-
tiple comparison tests, using SigmaStat® version 3.5 
(Systat Software Inc., 2006) and Minitab® version 
15 (Minitab Inc., 2007). Parametric tests (Student›s 
t-test and Pearson correlation) were adopted when 
the variable presented Gaussian behavior, otherwise, 
nonparametric tests were indicated (Mann-Whitney U 
and Kruskal-Wallis test combined with Dunn›s mul-
tiple comparisons test). A significance level of 5% 
was used for all calculations.
RESULTS
Clinical analysis: in general, all groups in-
creased body mass regardless of the substance ad-
ministered without, however, presenting any sig-
nificant difference (p = 0.05) (Chart 2). Increased 
body mass was significantly higher in oophorecto-
mized animals (p = 0.005) (Chart 3).
Taking into account the substance administered, 
within group O, the subgroup that received zoledronic 
acid (OZA) was found to have more body mass than 
the subgroup that received distilled water (ODW), 
without, however, a statistical difference (p = 0.47) 
Chart 2 – Mean body mass of groups throughout the experiment 
(p = 0.05).
(Chart 4). The same occurred with the sham surgery 
group (P) (p = 0.68) (Chart 5).
Biomechanical analysis: when comparing all four 
groups, we found that those who received zoledronic 
acid supported a greater compression force than those 
who did not use it, although without statistical diffe-
rence (p = 0.20) (Chart 6).
The average of the maximum load supported by the 
OZA group (109.2 N ± 14.9) was higher than that of 
the ODW group (98.6 N ± 15.4), with no statistical 
difference between these values (p = 0.14) (Chart 7). 
However, it was confirmed that the average maximum 
load supported by the OZA group (109.2 ± 14.9) was 
statistically the same as the PDW group (109.36 ± 10.2) 
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(p = 0.98) (Chart 8), when comparing the ODW and 
PDW groups, there is a tendency toward a difference 
(p = 0.08) (Chart 9).
Histomorphometric analysis: comparing the 
four groups, there is an increase in the median tra-
becular bone area in the groups that received zole-
dronic acid, although without statistical significance 
(p = 0.21) (Chart 10).
Chart 4 – Mean body mass in groups ODW and OZA throughout 
the experiment (p = 0.47).
Chart 5 – Mean body mass in groups PDW and PZA throughout 
the experiment (p = 0.68).
Chart 6 – Box plot of the median maximum load at the time of 
fracture in different groups (p = 0.20).
Chart 7 – Mean maximum load at the time of fracture in the ODW 
and OZA groups (p = 0.14).
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No difference was found when comparing the me-
dian tibial trabecular area of the ODW (153,923.5 
./20#&,1#234#-5678995#./2) groups (p = 0.15). Ho-
wever, it appears that the median of the trabecular 
&%"&#+:#$!"#234#;%+)<#-5678995#./2) was statistically 
$!"#=&/"#&=#;%+)<#>?@#-ABC8ADE#./2) (p = 0.90).
Linear regression analysis: performed using 
Pearson’s coefficient showed a strong positive
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correlation between the trabecular bone area and the 
maximum load supported by the specimen (p = 0.04, 
r = 0.95) (Chart 11).
DISCUSSION
Zoledronic acid, a powerful new bisphosphonate, 
inhibits osteoclast action and, consequently, decreases 
bone resorption(10,11). Trabecular bone is the main site 
of drug action, maintaining thickness and density of 
Chart 8 – Mean maximum load at the time of fracture in the OZA 
and PDW groups (p = 0.98).
Chart 9 – Mean maximum load at the time of fracture in the ODW 
and PDW groups (p = 0.08).
Chart 10 – Box plot of median trabecular bone area in the 
different groups (p = 0.21).
Chart 11 – Linear regression between the trabecular bone area 
and the maximum load (p = 0.04).
Rev Bras Ortop. 2009;44(1):61-8
bone connections and increasing their resistance to 
fracture(12-14). Patients with osteoporosis, especially 
primary type I (post-menopause) osteoporosis, who 
have high osteoclastic activity, can benefit from this 
third generation bisphosphonate by simply maintai-
ning their trabecular bone mass(25).
The rat was chosen for this study because it has 
characteristics similar to those of human beings in re-
lation to their musculoskeletal and hormonal systems, 
as well as their ease of handling, vivarium availability, 
and low cost(26-28).
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In terms of body mass, hormone-deprived animals, 
that is, oophorectomized (group O) animals had hi-
gher body mass gain than the sham surgery group 
(group P) (p = 0.005). Similar findings were obtai-
ned by other authors(26,29,30). After menopause, due to 
changes in not only the distribution of adipose tissue 
caused by estrogen deficiency but also in the accumu-
lation of peripheral fat, there is a change in the lipid 
profile and increased body mass(31). In this study, we 
did not find zoledronic acid to increase body mass, a 
fact demonstrated by Reid et al.(16), Hornby et al.(32), 
Otrock et al.(33), and Gilfillan et al.(34). We conclude 
therefore that the increase in body mass was caused 
by the removal of the ovaries (oophorectomy) and 
not by the substances administered.
In the biomechanical analysis comparing the maxi-
mum load supported by the tibiae in the four groups, 
we observed that the groups that received zoledronic 
acid showed an increased load at the time of fracture 
compared to those who did not receive it, although 
not constituting a statistical difference (p = 0.20), 
suggesting an increase in trabecular bone mass in 
those groups. These results were repeated during the 
analysis of the OZA and ODW groups, without a 
significant difference between groups (p = 0.14), but 
with a substantial increase in the maximum load in 
the group submitted to zoledronic acid. We know to-
day that bone resistance to fracture is due more to the 
quantity and quality of trabecular bone than cortical 
bone(17). This fact could explain the results, since the 
diaphyseal portion of the tibia has a lower amount of 
trabecular bone in proportion to cortical bone.
When comparing the trabecular bone area in the 
four groups histomorphometrically, it was observed 
that the groups that received zoledronic acid had a lar-
ger trabecular area, although without statistical signi-
ficance (p = 0.21). Analyzing the trabecular bone area 
of the oophorectomized groups, we found that the 
presence of zoledronic acid did not significantly alter 
the trabecular area (p = 0.15). However, the median 
trabecular area of the OZA group was statistically 
the same as the PDW group (p = 0.9), demonstrating 
that zoledronic acid had a positive effect in maintai-
ning the trabecular bone of that group. Patlas et al. 
analyzed the effect of oophorectomy on the diaphysis, 
metaphysis, and epiphysis of rats, observing a de-
crease in trabeculae only in the metaphyseal region. 
They concluded that oophorectomy exerts significant 
changes in the trabecular bone of long bones, espe-
cially in the extremities, and to a lesser extent in the 
middle region(24).
The dispersion analysis between the trabecular 
bone area and the maximum load supported by the 
body showed that these are positively correlated quan-
tities, that is, the maximum load supported by the 
specimen varies in proportion to the area of trabecular 
bone. Therefore, the amount of trabecular bone can be 
considered a predictive factor for fractures from oste-
oporosis. Other studies are needed to demonstrate the 
efficacy of zoledronic acid in other regions of tibia.
CONCLUSION
Zoledronic acid had no significant influence on the 
body mass of animals. Results showed that zoledro-
nic acid did not significantly increase bone strength 
of the tibial diaphysis or the trabecular area of dia-
physeal bone.
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